Merck & Co Inc (MRK)
127.51
-0.75
(-0.58%)
USD |
NYSE |
May 03, 16:00
127.59
+0.08
(+0.06%)
After-Hours: 20:00
Merck Enterprise Value: 351.00B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 351.00B |
| May 02, 2024 | 352.90B |
| May 01, 2024 | 354.27B |
| April 30, 2024 | 355.33B |
| April 29, 2024 | 357.61B |
| April 26, 2024 | 360.35B |
| April 25, 2024 | 359.13B |
| April 24, 2024 | 349.71B |
| April 23, 2024 | 349.41B |
| April 22, 2024 | 349.56B |
| April 19, 2024 | 346.62B |
| April 18, 2024 | 345.23B |
| April 17, 2024 | 345.58B |
| April 16, 2024 | 344.80B |
| April 15, 2024 | 347.66B |
| April 12, 2024 | 346.52B |
| April 11, 2024 | 347.56B |
| April 10, 2024 | 349.08B |
| April 09, 2024 | 348.98B |
| April 08, 2024 | 348.60B |
| April 05, 2024 | 352.22B |
| April 04, 2024 | 351.38B |
| April 03, 2024 | 357.06B |
| April 02, 2024 | 358.20B |
| April 01, 2024 | 359.82B |
| Date | Value |
|---|---|
| March 31, 2024 | 362.28B |
| March 28, 2024 | 362.28B |
| March 27, 2024 | 361.78B |
| March 26, 2024 | 346.00B |
| March 25, 2024 | 345.46B |
| March 22, 2024 | 341.76B |
| March 21, 2024 | 341.18B |
| March 20, 2024 | 341.76B |
| March 19, 2024 | 337.59B |
| March 18, 2024 | 335.66B |
| March 15, 2024 | 335.86B |
| March 14, 2024 | 333.30B |
| March 13, 2024 | 337.48B |
| March 12, 2024 | 338.75B |
| March 11, 2024 | 339.03B |
| March 08, 2024 | 340.88B |
| March 07, 2024 | 342.12B |
| March 06, 2024 | 341.51B |
| March 05, 2024 | 339.18B |
| March 04, 2024 | 342.27B |
| March 01, 2024 | 349.64B |
| February 29, 2024 | 350.12B |
| February 28, 2024 | 352.68B |
| February 27, 2024 | 354.80B |
| February 26, 2024 | 354.32B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
176.33B
Minimum
Mar 23 2020
362.28B
Maximum
Mar 28 2024
248.06B
Average
226.98B
Median
Enterprise Value Benchmarks
| Amgen Inc | 221.30B |
| Johnson & Johnson | 366.66B |
| Eli Lilly and Co | 722.23B |
| Pfizer Inc | 215.90B |
| Moderna Inc | 39.38B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.762B |
| Revenue (Quarterly) | 15.78B |
| Total Expenses (Quarterly) | 10.02B |
| EPS Diluted (Quarterly) | 1.87 |
| Gross Profit Margin (Quarterly) | 77.56% |
| Profit Margin (Quarterly) | 30.19% |
| Earnings Yield | 0.71% |
| Operating Earnings Yield | 1.51% |
| Normalized Earnings Yield | 0.9546 |